Actelion drops tezosentan, reports earnings

In its 1Q08 earnings, Actelion (SWX:ATLN) disclosed that it discontinued development of tezosentan. The company said the decision was made because "the observed event rate and effect in a recently concluded study in cardiac bypass separation was lower than expected and would have required far larger studies than anticipated." The endothelin receptor antagonist was in Phase III testing to treat right ventricular failure (RVF) associated with difficult separation from bypass (DSB) in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). ...